VEGFA and retinopathy of prematurity: The largest anti-VEGF study for ROP to date, the BEAT-ROP (efficacy of intravitreal bevacizumab for stage 3 + retinopathy of prematurity) trial, found that bevacizumab, a full-size anti-VEGF antibody, can halt the progression of severe ROP, revert pathologic angiogenic changes, and induce the progression of physiologic intraretinal vasculature [6].